drug · protein
patient view →carfilzomib
Marketedupdated 2mo agoby $AMGN AMGEN INC🔗 ChEMBL
Approvedcommunity read0 votes
Protein drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and multiple myeloma and 12 investigational indications.
targets
26S proteasome
all catalysts(0)
nothing on the calendar yet
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that